Heat tolerance of Boran and Tuli crossbred steers.

Experiments were conducted to evaluate the heat tolerance of the following breeds: Hereford (H), Brahman (B), H x B, H x Boran (H x Bo), and H x Tuli (H x T). Heat tolerance was evaluated in a climatically controlled room (Exp. 1) and under summer environmental conditions (Exp. 2) by comparing rectal temperatures (RT), respiration rates (RR), and sweating rates (SW). In Exp. 1, under extremely hot conditions (mean temperature-humidity index [THI] > 90), purebred B had significantly (P < .05) lower RT and RR than other genotypes, which may be indicative of greater surface area per mass to dissipate heat and a lower metabolic rate than other genotypes. Boran and Tuli crosses had RT (39.5 degrees C) that were intermediate to those of B (39.0 degrees C) and H x B (40.0 degrees C). The H genotype had the greatest RT at 40.3 degrees C. Among the breeds, trends in RR were similar to RR observed at THI < 77; B had the lowest RR, and H x B were intermediate. However, in these extreme conditions, RR did not differ among the purebred H and the Boran and Tuli crossbred steers, but H x B steers had lower RR than the other H crossbred steers. Sweating rates were significantly greater for the Bos indicus x Bos taurus crosses (H x B and H x Bo) than for the purebred genotypes (H and B) and the Bos taurus cross (H x T). In Exp. 2, mean RT for B, H x B, H x Bo, and H x T were very similar to those recorded under the moderate heat stress conditions found in Exp. 1. There were no differences in RT among B, H x Bo, and H x T genotypes. The RR increased over time for H only, and RR for other genotypes tended to be elevated only slightly over time. Among genotypes, SW was significantly greater for the H x Bo steers. The ability of the Bos indicus crosses to dissipate heat through enhanced SW and associated evaporative cooling was evident. However, the heat-tolerant nature of the Bos taurus cross (H x T) was not evident through enhanced RR or SW in either experiment. Compared with other genotypes, the lower RR of B steers was clearly evident and is assumed to be due to greater surface area and other skin characteristics that allow them to dissipate heat to maintain lower RT. These data suggest that the H x Bo and H x T are similar to H x B and intermediate to H and B genotypes in maintaining homeostasis when exposed to a high heat load.     

Effect of Satiate or Restricted Feeding on Golden Shiner Notemigonus crysoleucas Production in Earthen Ponds

Abstract.— This study was conducted to evaluate the effects of satiate or restricted feeding on the growth and production of golden shiners Notemigonus crysoleucas . Golden shiners (1.2 g) stocked at 560 kg/ha in 12,0.04-ha earthen ponds for 79 d grew to average weights of 5.6, 4.6 and 3.8 g for fish fed to satiation, or 75% or 50% of that amount, respectively. Gross yield ranged from 811 to 1,277 kg/ha; net yield did not differ significantly among treatments.     

Pharmacokinetics and lung tissue concentrations of tulathromycin in swine

The absolute bioavailability and lung tissue distribution of the triamilide antimicrobial, tulathromycin, were investigated in swine. Fifty-six pigs received 2.5 mg/kg of tulathromycin 10% formulation by either intramuscular (i.m.) or intravenous (i.v.) route in two studies: study A (10 pigs, i.m. and 10 pigs, i.v.) and study B (36 pigs, i.m.). After i.m. administration the mean maximum plasma concentration (C(max)) was 616 ng/mL, which was reached by 0.25 h postinjection (t(max)). The mean apparent elimination half-life (t(1/2)) in plasma was 75.6 h. After i.v. injection plasma clearance (Cl) was 181 mL/kg.h, the volume of distribution at steady-state (V(ss)) was 13.2 L/kg and the elimination t(1/2) was 67.5 h. The systemic bioavailability following i.m. administration was >87% and the ratio of lung drug concentration for i.m. vs. i.v. injection was > or =0.96. Following i.m. administration, a mean tulathromycin concentration of 2840 ng/g was detected in lung tissue at 12 h postdosing. The mean lung C(max) of 3470 ng/g was reached by 24 h postdose (t(max)). Mean lung drug concentrations after 6 and 10 days were 1700 and 1240 ng/g, respectively. The AUC(inf) was 61.4 times greater for the lung than for plasma. The apparent elimination t(1/2) for tulathromycin in the lung was 142 h (6 days). Following i.m. administration to pigs at 2.5 mg/kg body weight, tulathromycin was rapidly absorbed and highly bioavailable. The high distribution to lung and slow elimination following a single dose of tulathromycin, are desirable pharmacokinetic attributes for an antimicrobial drug indicated for the treatment of respiratory disease in swine.     

Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs

OBJECTIVE: To determine whether exposure of canine osteosarcoma cells to deracoxib or piroxicam results in decreased viability, whether the cytotoxic effects of deracoxib and piroxicam involve induction of apoptosis, and whether deracoxib is a more potent inhibitor of osteosarcoma cell growth than piroxicam. SAMPLE POPULATION: 1 fibroblast and 3 osteosarcoma cell lines. PROCEDURE: Cell counts and viability assays were performed using osteosarcoma cells (POS, highly metastatic POS, and canine osteosarcoma cell 31) and fibroblasts after 72 hours of incubation with deracoxib at concentrations of 0.5 microM to 500 microM or piroxicam at concentrations of 1 microM to 1,000 microM. Percentage viability was determined for each concentration. A DNA fragmentation analysis was performed to assess drug-induced apoptosis. RESULTS: Concentration of deracoxib required for 50% inhibition of cell viability (IC50) was reached in all 3 osteosarcoma cell lines and ranged from 70 to 150 microM, whereas the IC50 for piroxicam was only reached in the POS cell line at 500 microM. Neither deracoxib nor piroxicam induced sufficient toxicity in fibroblasts to reach an IC50. Exposure of osteosarcoma cells to cytotoxic concentrations of deracoxib and piroxicam did not result in DNA fragmentation. CONCLUSIONS AND CLINICAL RELEVANCE: Intermediate and high concentrations of deracoxib and high concentrations of piroxicam were cytotoxic to osteosarcoma cells; neither drug inhibited cell viability at typical plasma concentrations in dogs. Deracoxib inhibited viability of cells at concentrations that did not affect fibroblast viability. There was no evidence of apoptosis induction for either drug; however, only 1 cell line was evaluated for apoptosis induction and only for a limited selection of drug concentrations.     

Stereotactic radiosurgery for treatment of osteosarcomas involving the distal portions of the limbs in dogs

Stereotactic radiosurgery (SRS) involves precise delivery of a single large dose of radiation to a designated tumor target. This report describes use of SRS in combination with a frameless stereotactic localization system to treat 11 dogs with appendicular osteosarcomas. Five dogs were treated with SRS alone; 6 were treated with a combination of SRS and chemotherapy. Overall median survival time was 363 days (range, 145 to 763 days), with 6 dogs still alive 90, 142, 234, 367, 633, and 763 days after SRS. Limb function was good or excellent in all 6 dogs that were still alive. Results in these dogs suggest that SRS may be a viable option for dogs with appendicular osteosarcoma, with the potential to provide long-term local tumor control and improvement in limb function, especially when combined with chemotherapy. Because of the destructive nature of osteosarcoma and limitations of SRS, dogs with tumors that are small and have caused minimal bone destruction would likely be the best candidates for this procedure.     

OUTCOMES AND PROGNOSTIC FACTORS ASSOCIATED WITH CANINE SINONASAL TUMORS TREATED WITH CURATIVE INTENT CONE‐BASED STEREOTACTIC RADIOSURGERY (1999–2013)

Stereotactic radiosurgery (SRS) is a relatively new therapeutic option in veterinary oncology. The role of this modality has not been extensively evaluated for the use in canine nasal tumors. The objective of this retrospective, observational study was to describe the clinical outcome and prognostic factors associated with survival times in a sample of canine patients treated with SRS for sinonasal tumors. Fifty‐seven dogs with sinonasal tumors met inclusion criteria. Histologic diagnoses included sarcoma (SA) (n = 9), carcinoma (CA) (n = 40), osteosarcoma (OSA) (n = 7), and round cell (n = 1). Four of 57 cases were treated twice with SRS. For these, the median and mean doses delivered were 30Gy and 33Gy, respectively (range 18.75Gy–56Gy). Late effects occurred in 23 cases and ranged from grades I–III. The median overall survival time was 8.5 months. The median overall survival times in dogs with tumor type of CA, SA, and OSA were 10.4, 10.7, and 3.1 months, respectively. Dogs with the tumor type of OSA had shorter overall survival time than that in dogs with tumor type of CA and SA. Findings from this retrospective study indicated that SRS may be beneficial for canine patients with sinonasal tumors, however a controlled clinical trial would be needed to confirm this. Prospective studies are also needed to better define the role of SRS as palliative or curative, and to further investigate the risk of clinically significant toxicity.